-
Biocon, Anthem Biosciences, Onesource Specialty Pharma and Sai Life Sciences Leading BioTech Innovation in India
25 Oct 2025 06:46 GMT
… . With headquarters in Bangalore, Biocon champions accessibility and affordability in … for chronic diseases, targeting diabetes, cancer, and autoimmune disorders.
Achievements … Future
The collective strength of Biocon, Anthem Biosciences, Onesource Specialty …
-
'I am amused': Kiran Mazumdar-Shaw offered to repair Bengaluru roads? Biocon chief responds to P Chidambaram
23 Oct 2025 06:48 GMT
Biocon chief Kiran Mazumdar-Shaw on … the IT hub. But the Biocon chief has denied making any … : 'Silent killer' pancreatic cancer symptoms might show up in …
-
New Drugs Show Promise In Tough-To-Treat Cancers
22 Oct 2025 16:22 GMT
… Chair Could Revolutionize Cancer Radiation Therapy
For decades … deliver targeted radiation to cancerous tumors, are massive contraptions … receiving standard treatment.
Cancer detection. Diagnostics company … Kiran Mazumdar Shaw’s Biocon Biologics, a leader …
-
India News | Biocon Chief Kiran Mazumdar-Shaw Meets Karnataka Deputy CM DK Shivakumar
21 Oct 2025 07:21 GMT
… ) [India], October 21 (ANI): Biocon chief and industrialist Kiran Mazumdar … Dupe 83-Year-Old Cancer Patient of INR 82 Lakh … kiranshaw, entrepreneur and Founder of Biocon, at my residence today. We … took a jibe at Biocon chairperson Kiran Mazumdar-Shaw …
-
Biocon Chief Kiran Mazumdar-Shaw applauds new antibody optimisation method to tackle resistant tumours
17 Oct 2025 20:06 GMT
New Delhi: Biocon Chairperson and Founder, Kiran Mazumdar- … , published in the journal Molecular Cancer Therapeutics, the researchers engineered a … hope for patients with advanced cancers," said the researchers from …
-
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com
07 Oct 2025 13:56 GMT
… in curing such illnesses as cancer, diabetes, and rare genetic … are enhancing the treatment of cancer, rare genetic diseases, and … with interest in mRNA-based cancer and infectious disease treatments.
The … AG
Amgen Inc.
Syngenta AG
Biocon Limited
Biogen Inc.
F. …
-
Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
01 Oct 2025 11:21 GMT
… osteoporosis and cancer-related bone conditions.
Biocon Biologics and … for nonmetastatic prostate cancer, and to increase … therapy for breast cancer.
AUKELSO is approved … : Equity Bulls
Keywords
Biocon
INE376G01013
Biotechnology
BioconBiologics
Settlement …
-
Biocon Biologics, Amgen strike settlement, clear path for Bosaya, Aukelso in US
01 Oct 2025 09:19 GMT
… company and subsidiary of Biocon Ltd., has announced a … therapy for nonmetastatic prostate cancer, and to increase bone … , associated with BOSAYA.
Biocon Biologics and Amgen executed … CEO & Managing Director, Biocon Biologics, said, “This settlement …
-
Biocon Biologics secures U.S. launch for Bosaya and Aukelso following settlement with Amgen
01 Oct 2025 05:14 GMT
… ). Both treatments target osteoporosis and cancer-related bone conditions, offering patients … District of New Jersey, allowing Biocon Biologics to officially launch Bosaya … remain confidential.
This development strengthens Biocon Biologics’ footprint in the U …
-
FDA Approves Biocon’s Denosumab Biosimilars
26 Sep 2025 18:05 GMT
… 16, 2025, the FDA approved Biocon Biologics Ltd.’s BOSAYA™ (denosumab … conditions such as osteoporosis and cancer-related skeletal complications. According to … efficacy to the reference product.
Biocon’s denosumab biosimilars are the …
About
© 1995-2025